科济药业-B今日盘中大跌5.04%，报23.74港元/股，成交额约8073万港元。
消息面上，科济药业此前因自主研发的舒瑞基奥仑赛注射液（satri-cel）研究成果在国际顶级医学期刊《柳叶刀》正式刊载，盘中一度大涨逾10%。该成果标志着公司在实体瘤CAR-T疗法领域取得重要突破。然而，利好消息兑现后，股价连续两个交易日回落，累计回吐前期涨幅。当前股价已回落至利好发布前水平附近，短期获利盘出清压力较为明显。
科济药业-B今日盘中大跌5.04%，报23.74港元/股，成交额约8073万港元。
消息面上，科济药业此前因自主研发的舒瑞基奥仑赛注射液（satri-cel）研究成果在国际顶级医学期刊《柳叶刀》正式刊载，盘中一度大涨逾10%。该成果标志着公司在实体瘤CAR-T疗法领域取得重要突破。然而，利好消息兑现后，股价连续两个交易日回落，累计回吐前期涨幅。当前股价已回落至利好发布前水平附近，短期获利盘出清压力较为明显。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.